{"type":"trials","record":{"id":41488,"source_id":"clinicaltrials-gov","external_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","brief_summary":"The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that affects the central part of the retina and can cause vision loss in older adults. DME (diabetic macular edema): a swelling in the central part of the retina caused by diabetes, which can also lead to vision problems. RVO (retinal vein occlusion): a blockage of the veins in the retina, which can cause sudden vision loss. Researchers will look at data collected from 2009 to 2024 to see how often these diseases occur (incidence) and how many people have them at a given time (prevalence). They will use two large sets of health data from Germany, called FDZ and FDGP. The main question is: How do the numbers of new and existing cases of nAMD, DME, and RVO compare between the two data sources (FDZ and FDGP) in Germany from 2009 to 2024? The study also wants to find out if factors like age, other health problems, and medications affect how common these eye diseases are. Another goal is to see how many people with these eye diseases are treated with a type of medicine called anti-VEGF, which is used to slow down or stop vision loss. In summary, this study will help us understand how these eye diseases affect people in Germany, how they are treated, and whether different groups of people are more likely to get them.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Bayer","enrollment":50000,"countries":["Germany"],"start_date":"2026-03-03","completion_date":"2026-12-31","last_update_date":"2026-06-22","source_url":"https://clinicaltrials.gov/study/NCT07308639","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Bayer","interventions":["anti-VEGF medication"],"registry_source":"ClinicalTrials.gov","outcome_measures":["incidence of nAMD, DME and RVO of FDZ and FDPG in Germany — 1 Jan 2009 - 31 Dec 2024","prevalence of nAMD, DME and RVO in Germany — 1 Jan 2009 - 31 Dec 2024","incidence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and da…","prevalence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and d…","Number of patients with nAMD, DME, and RVO treated with anti-VEGF medications — 1 Jan 2009 - 31 Dec 2024","Proportion of patients with nAMD, DME, and RVO treated with anti-VEGF medications — 1 Jan 2009 - 31 Dec 2024"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)","anti-VEGF medication"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07308639","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-03 to 2026-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.821Z","intervention":["anti-VEGF medication"],"participants":50000,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["incidence of nAMD, DME and RVO of FDZ and FDPG in Germany — 1 Jan 2009 - 31 Dec 2024","prevalence of nAMD, DME and RVO in Germany — 1 Jan 2009 - 31 Dec 2024","incidence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and da…","prevalence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and d…","Number of patients with nAMD, DME, and RVO treated with anti-VEGF medications — 1 Jan 2009 - 31 Dec 2024","Proportion of patients with nAMD, DME, and RVO treated with anti-VEGF medications — 1 Jan 2009 - 31 Dec 2024"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related, older adult.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41488","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}